Literature DB >> 31100555

Factors Associated with Physician-Patient Discordance in the Perception of Asthma Control.

Kazuto Matsunaga1, Kazuki Hamada2, Keiji Oishi3, Masafumi Yano3, Yoshikazu Yamaji2, Tsunahiko Hirano2.   

Abstract

BACKGROUND: Physicians' perception of asthma control has a direct impact on treatment options and patients' outcomes.
OBJECTIVE: To analyze the differences between patients and their physicians in the perception of asthma control. Moreover, factors associated with this discordance were explored.
METHODS: A multicenter, cross-sectional survey was conducted in patients visiting primary or secondary facilities for routine asthma reviews. Before the review, patients completed the 5-iteam Asthma Control Questionnaire (ACQ) under the supervision of a medical staff. Physicians recorded their perception of the patients' asthma control without viewing the ACQ results. After the review, physicians completed the demographic and clinical data.
RESULTS: A total of 1697 patients were included. ACQ results showed that asthma was well controlled in 52.2% of the patients, but physicians perceived that 79.6% of patients were well controlled. The concordance analyzed by the kappa index was weak (0.27). The discordant physician-patient pairs had significantly worse ACQ scores than the concordant pairs (P < .0001), but the use of neither inhaled corticosteroids nor other controller medications showed any differences between the groups. In a multivariate model, ACQ score of 0.75 or more and lack of lung function assessment within the previous 6 months were independently associated with the physician-patient discordance in the perception of asthma control.
CONCLUSIONS: The subjective perception of the physicians did not show a good agreement with the patients' asthma control based on validated ACQ scores, with increased rates of discordance among patients whose asthma was not well controlled and patients who had not received lung function assessment.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy; Asthma; Inflammation; Lung function

Year:  2019        PMID: 31100555     DOI: 10.1016/j.jaip.2019.04.046

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

1.  Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.

Authors:  Nozomi Tani; Nobutaka Kataoka; Yusuke Kunimatsu; Yusuke Tachibana; Takumi Sugimoto; Izumi Sato; Yuri Ogura; Kazuki Hirose; Takayuki Takeda
Journal:  Multidiscip Respir Med       Date:  2021-03-17

Review 2.  Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach.

Authors:  Kazuki Hamada; Keiji Oishi; Yoriyuki Murata; Tsunahiko Hirano; Kazuto Matsunaga
Journal:  J Asthma Allergy       Date:  2021-12-07

3.  Assessment of Predictor Factors Associated with Multiple Emergency Department Attendance with Asthma Attack: A Qualitative and Multicentric Prospective Observational Study.

Authors:  Prabakar Vaittinada Ayar; Camille Taillé; Pradeebane Vaittinada Ayar; Matthieu Gay; Alhassane Diallo; Aïchata Fofana Dara; Olivier Peyrony; Olivier Chassany; Enrique Casalino
Journal:  J Asthma Allergy       Date:  2022-03-05

4.  Improved inhaler handling after repeated inhalation guidance for elderly patients with bronchial asthma and chronic obstructive pulmonary disease.

Authors:  Osamu Usami
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

Review 5.  Breaking the vicious circle-the Asthma Referral Identifier (ReferID) tool.

Authors:  Maarten Beekman; Julie Hales; Mona Al-Ahmad; Ricardo Del Olmo; Tze Lee Tan
Journal:  NPJ Prim Care Respir Med       Date:  2022-10-08       Impact factor: 3.289

6.  Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study).

Authors:  Yasuo Shimizu; Taichi Shiobara; Ryo Arai; Kazuyuki Chibana; Akihiro Takemasa
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.